Istituto Nazionale Tumori IRCCS Fondazione G. Pascale Selects MEVION S250-FIT™ for Southern Italy’s First Proton Therapy Center

Why It Matters

The new center expands access to state‑of‑the‑art cancer care in a historically underserved region, reducing travel burdens and setting a template for compact proton therapy adoption across European health systems.

Key Takeaways

• First proton therapy center in Southern Italy opens in Naples
• MEVION S250‑FIT fits into standard radiotherapy vaults
• Compact system cuts capital costs versus traditional multi‑room sites
• Collaboration adds upright positioning and RaySearch planning tools
• Project signals broader European rollout of single‑room proton therapy

Pulse Analysis

Proton therapy has long been hampered by the size and expense of traditional accelerators, limiting its rollout to a handful of high‑budget centers. Mevion’s S250‑FIT tackles these barriers with a single‑room design that slots into existing LINAC vaults, eliminating the need for massive gantries and dedicated buildings. By offering FDA clearance and CE‑marking, the platform aligns with both U.S. and European regulatory expectations, making it a versatile option for hospitals seeking to upgrade their radiotherapy portfolios without massive capital outlays.

In Naples, the partnership between Fondazione Pascale, Mevion, Leo Cancer Care, Morveducci, and RaySearch creates a turnkey solution that blends compact hardware with upright patient positioning and advanced treatment‑planning software. This integration enables the center to deliver intensity‑modulated proton therapy and the emerging DirectARC™ arc technique within a workflow familiar to conventional radiotherapy teams. For Southern Italy’s patients, the facility reduces travel distances that previously required journeys to northern hubs, improving treatment adherence and overall equity in cancer care.

Strategically, the award underscores Mevion’s ambition to scale its compact systems across Europe, where many health systems face budget constraints and space limitations. The success at Fondazione Pascale may encourage other regional cancer networks to consider similar single‑room installations, intensifying competition with larger multi‑room vendors. As more institutions adopt cost‑effective proton solutions, the technology could transition from a niche offering to a mainstream component of oncology treatment arsenals, reshaping market dynamics and accelerating patient access to high‑precision radiation therapy.